However, in a recent phase II trial, chemotherapy-naïve patients harboring activating EGFR mutations with stage IIIB/IV or post-surgical recurrent non-squamous NSCLC were treated with erlotinib induction at 150 mg/day for 3 months, followed by cytotoxic chemotherapy with platinum plus pemetrexed, with or without bevacizumab. Here, EGFR is linked to non-small cell lung carcinoma.